• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors

    8/1/25 9:28:00 AM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PTHL alert in real time by email

    BEIJING, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the "Company," "we," "our" or "Pheton"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today issued the following statements in response to recent market volatility and a third-party publication that has raised questions and concerns among shareholders.

    Over the past few days, shares of Pheton have experienced an extraordinary and unexpected decline in its share price, which the Company believes may have been triggered by a speculative article published by The Bear Cave on July 29, 2025. The article asserts that Pheton's share price may have been influenced by false rumors of a potential acquisition by Gilead Sciences, Inc. ("Gilead").

    Management's Position and Clarification

    Pheton's management team unequivocally and categorically denies any involvement in, or knowledge of, any form of stock price manipulation. At no point has the Company participated in, initiated, or sanctioned any rumor, communication, or activity regarding an acquisition by Gilead, or any other party. Pheton has had no contact with Gilead, and any statements or reports suggesting otherwise were and are entirely false and fabricated.

    Additionally, Pheton plans to engage with its market makers, Nasdaq, and relevant regulatory bodies for the purpose of holding responsible parties to the scheme accountable.

    Protecting Shareholder Interests

    We recognize the concern this incident has caused among our investors, and we are monitoring internal controls and communications to ensure that any further misinformation can be swiftly and effectively countered.

    Commitment to Transparency and Growth

    Pheton is committed to upholding the highest standards of corporate governance, transparency, and accountability. As always, we remain focused on creating long-term shareholder value through carefully considered growth opportunities that align with our mission and strengthen our market position.

    Pheton has built its foundation on trust, innovation, and value creation and remains confident in the strength of its underlying business, long-term strategy, and the dedication of its team.

    A Word to Our Shareholders

    We deeply value the trust our shareholders place in us. We will continue to keep the investor community informed with accurate and timely disclosures. Our leadership remains focused on operational execution and strengthening the integrity of our public market presence.

    About Pheton Holdings Ltd

    Founded in 1998, Pheton Holdings Ltd, through its wholly owned operating subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd. ("Beijing Feitian"), focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its lead product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Pheton is committed to leveraging its products and services to establish a potential new standard of care across multiple malignant tumor applications. For more information, please visit: http://www.ftzy.com.cn/ir/

    Forward-Looking Statements

    Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the U.S. Securities and Exchange Commission.

    For investor and media inquiries, please contact:

    Pheton Holdings Ltd

    Investor Relations

    Email: [email protected]

    Jackson Lin

    Lambert by LLYC

    Tel: +1 (646) 717-4593

    Email: [email protected]

    ###



    Primary Logo

    Get the next $PTHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTHL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pheton Holdings Ltd Announces Corporate Name Change and Stock Ticker Symbol Change

    BEIJING, China, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the "Company" or "Pheton"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, announced today that it will change its corporate name to iTonic Holdings Ltd, and change its stock ticker symbol to "ITOC" (collectively, the "Corporate Events"). The Company anticipates that the Corporate Events will be effective upon the commencement of trading on the Nasdaq Capital Market on January 16, 2026 (U.S. Eastern Time), at which time the Company's Class A ordinary shares will cease trading under the current ticker symbol "PTHL" and will begin tradi

    1/13/26 8:30:00 AM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pheton Holdings Ltd Announces Closing of Share Acquisition with iTonic Corporation

    Beijing, China, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ:PTHL) ("Pheton" or the "Company"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced the successful completion of its acquisition of 51% of the total outstanding shares of iTonic Corporation (the "Target"), a U.S.-based integrated home health AI company that combines AI, medical device automation, and easier access to clinical expertise to support continuity of care in the home (the "Share Acquisition"). This strategic acquisition aligns with the Company's commitment to enhancing its portfolio in the healthcare tech

    12/5/25 4:05:00 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Beijing, China, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ:PTHL) (the "Company"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced, on October 20, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that based on the closing bid price of the Class A ordinary shares of the Company for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. Th

    10/23/25 4:15:00 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $PTHL
    SEC Filings

    View All

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    1/13/26 4:00:30 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    12/22/25 7:43:23 AM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Pheton Holdings Ltd

    6-K - Pheton Holdings Ltd (0001970544) (Filer)

    12/16/25 12:58:56 PM ET
    $PTHL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care